JP2021522862A5 - - Google Patents

Info

Publication number
JP2021522862A5
JP2021522862A5 JP2021513004A JP2021513004A JP2021522862A5 JP 2021522862 A5 JP2021522862 A5 JP 2021522862A5 JP 2021513004 A JP2021513004 A JP 2021513004A JP 2021513004 A JP2021513004 A JP 2021513004A JP 2021522862 A5 JP2021522862 A5 JP 2021522862A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
lipid group
group
lipid
conjugate according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021513004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522862A (ja
JP7665509B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/062064 external-priority patent/WO2019215333A1/en
Publication of JP2021522862A publication Critical patent/JP2021522862A/ja
Publication of JP2021522862A5 publication Critical patent/JP2021522862A5/ja
Application granted granted Critical
Publication of JP7665509B2 publication Critical patent/JP7665509B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021513004A 2018-05-11 2019-05-10 7’-5’-アルファ-アノマー二環式糖ヌクレオシドを含むオリゴヌクレオチドコンジュゲート Active JP7665509B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862670319P 2018-05-11 2018-05-11
US62/670,319 2018-05-11
PCT/EP2019/062064 WO2019215333A1 (en) 2018-05-11 2019-05-10 Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides

Publications (3)

Publication Number Publication Date
JP2021522862A JP2021522862A (ja) 2021-09-02
JP2021522862A5 true JP2021522862A5 (cg-RX-API-DMAC10.html) 2024-06-07
JP7665509B2 JP7665509B2 (ja) 2025-04-21

Family

ID=66530048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021513004A Active JP7665509B2 (ja) 2018-05-11 2019-05-10 7’-5’-アルファ-アノマー二環式糖ヌクレオシドを含むオリゴヌクレオチドコンジュゲート

Country Status (11)

Country Link
US (2) US20230132377A9 (cg-RX-API-DMAC10.html)
EP (1) EP3790968A1 (cg-RX-API-DMAC10.html)
JP (1) JP7665509B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210008369A (cg-RX-API-DMAC10.html)
CN (1) CN112424352A (cg-RX-API-DMAC10.html)
AU (1) AU2019266550A1 (cg-RX-API-DMAC10.html)
BR (1) BR112020022620A2 (cg-RX-API-DMAC10.html)
CA (1) CA3098266A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202010841QA (cg-RX-API-DMAC10.html)
WO (1) WO2019215333A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202007564B (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3330276A1 (en) * 2016-11-30 2018-06-06 Universität Bern Novel bicyclic nucleosides and oligomers prepared therefrom
CA3098623A1 (en) 2018-05-07 2019-11-14 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
WO2021054370A1 (ja) * 2019-09-18 2021-03-25 国立大学法人東京医科歯科大学 核酸複合体
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP4213883A1 (en) * 2020-09-16 2023-07-26 Astrazeneca AB Oligonucleotides conjugated to fatty acids
AU2021382146A1 (en) * 2020-11-23 2022-05-27 Alpha Anomeric Sas Nucleic acid duplexes
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
AU2023404700A1 (en) 2022-12-02 2025-07-10 Shanghai Argo Biopharmaceutical Co., Ltd. Bicyclic abasic nucleic acid analogs and oligomeric compounds prepared therefrom
WO2025217304A1 (en) * 2024-04-09 2025-10-16 Bio-Rad Laboratories, Inc. Compositions and methods for detection of contaminant enzymes

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0500799B1 (en) 1989-11-16 1998-01-14 Duke University Particle mediated transformation of animal skin tissue cells
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
AU649074B2 (en) 1990-10-12 1994-05-12 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Modified ribozymes
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
AU6044994A (en) 1993-02-19 1994-09-14 Nippon Shinyaku Co. Ltd. Glycerol derivative, device and pharmaceutical composition
TW404844B (en) 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6218108B1 (en) 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
JP2000325085A (ja) * 1999-05-21 2000-11-28 Masafumi Matsuo デュシェンヌ型筋ジストロフィー治療剤
US6653467B1 (en) * 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
AU2003225410A1 (en) * 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
US20080213891A1 (en) 2004-07-21 2008-09-04 Alnylam Pharmaceuticals, Inc. RNAi Agents Comprising Universal Nucleobases
WO2007030167A1 (en) 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification of double-stranded ribonucleic acid molecules
EA201100811A1 (ru) * 2006-04-03 2012-06-29 Сантарис Фарма А/С Фармацевтическая композиция
WO2010036698A1 (en) * 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
KR101981705B1 (ko) 2010-05-28 2019-05-24 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
CA2889044A1 (en) * 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
CA2893801A1 (en) * 2013-01-30 2014-08-07 F. Hoffmann-La Roche Ag Lna oligonucleotide carbohydrate conjugates
CN106581043A (zh) * 2016-10-24 2017-04-26 佳木斯大学 一种适用于杜氏肌营养不良症的药物制剂及其制备方法
EP3330276A1 (en) * 2016-11-30 2018-06-06 Universität Bern Novel bicyclic nucleosides and oligomers prepared therefrom

Similar Documents

Publication Publication Date Title
CN1964967B (zh) 路易斯酸介导的环状酯的合成
CN106795197B (zh) 改性寡核苷酸及其制备方法
CA2799501C (en) Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
JP2022173349A5 (cg-RX-API-DMAC10.html)
Le Corre et al. Atherton–Todd reaction: mechanism, scope and applications
JP2898750B2 (ja) 有機リン化合物をイオウ化するための方法およびそのための試薬
JP2022513719A5 (cg-RX-API-DMAC10.html)
JP2020503049A5 (cg-RX-API-DMAC10.html)
KR102933365B1 (ko) 뉴클레오티드 조성물 및 이의 방법
JP6770553B2 (ja) アルコキシフェニル誘導体、ヌクレオシド保護体およびヌクレオチド保護体、オリゴヌクレオチド製造方法、ならびに、置換基除去方法
WO2005028494A1 (ja) 5'-ホスフィチル化モノマーおよびh-ホスホネートオリゴヌクレオチド誘導体の製造方法
JP2022081575A5 (cg-RX-API-DMAC10.html)
JP2013138681A5 (cg-RX-API-DMAC10.html)
JP2022533421A5 (cg-RX-API-DMAC10.html)
CN102256987A (zh) 羟甲基膦酸酯、聚氨酯泡沫形成组合物、聚氨酯泡沫以及由其制成的制品的制造方法
JP2021526017A5 (cg-RX-API-DMAC10.html)
JP2021506246A5 (cg-RX-API-DMAC10.html)
JP5749016B2 (ja) 骨組織を標的としたベクターとしてのヒドロキシ‐ビスホスホン酸誘導体
EA003091B1 (ru) Синтез олигонуклеотидов в жидкой фазе
JP2024501288A5 (cg-RX-API-DMAC10.html)
WO2008141799A1 (en) Oligophosphoramidates
KR102186143B1 (ko) 티올 관능기를 포함하는 개질된 올리고뉴클레오티드 및 이를 이용한 핵산의 검출
JP2018518167A5 (cg-RX-API-DMAC10.html)
JP2004526737A5 (cg-RX-API-DMAC10.html)
Krishna et al. Solid-Phase Synthesis, Thermal Denaturation Studies, Nuclease Resistance, and Cellular Uptake of (Oligodeoxyribonucleoside) methylborane Phosphine–DNA Chimeras